The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease
One-year results
Whady Hueb, MD*,*,
Paulo R. Soares, MD*,
Bernard J. Gersh, MB, ChB, DPhil ,
Luiz A. M. César, MD*,
Protásio L. Luz, MD, FACC*,
Luiz B. Puig, MD*,
Eulógio M. Martinez, MD, FACC*,
Sergio A. Oliveira, MD* and
José A. F. Ramires, MD, FACC*
* Heart Institute of the University of São Paulo, São Paulo, Brazil
Mayo Clinic, Rochester, Minnesota, USA

View larger version (21K):
[in a new window]
|
Figure 1 Probability of survival free of cardiac mortality, unstable angina requiring revascularization, and myocardial infarction among patients in the three treatment groups: medical therapy (MT), coronary artery bypass graft surgery (CABG), and percutaneous coronary intervention (PCI).
|
|

View larger version (20K):
[in a new window]
|
Figure 2 Probability of survival free of cardiac-related mortality among patients in the three treatment groups: MT, CABG, and PCI. Abbreviations as in Figure 1.
|
|

View larger version (21K):
[in a new window]
|
Figure 3 Freedom from additional revascularization after study entry among patients in the three treatment groups: MT, CABG, and PCI. Abbreviations as in Figure 1.
|
|

View larger version (18K):
[in a new window]
|
Figure 4 Freedom from additional CABG after study entry among patients in the three treatment groups: MT, CABG, and PCI. Abbreviations as in Figure 1.
|
|

View larger version (17K):
[in a new window]
|
Figure 5 Freedom from additional PCI after study entry among patients in the three treatment groups: MT, CABG, and PCI. Abbreviations as in Figure 1.
|
|
|